Breast Neoplasm clinical trials

Explore recruiting breast neoplasm clinical trials.

Recruiting breast neoplasm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Breast Neoplasm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

I3Y-MC-JPEF: postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy

Italy, Czechia, Greece, Hungary, Belgium, Denmark +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (TDXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Spain, Germany, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)

Spain, Germany, Italy, Austria, Belgium, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Breast Neoplasm trials by city

Breast Neoplasm in Toronto Breast Neoplasm in Vancouver Breast Neoplasm in Montreal Breast Neoplasm in Calgary Breast Neoplasm in Edmonton Breast Neoplasm in Ottawa Breast Neoplasm in Winnipeg Breast Neoplasm in Quebec City Breast Neoplasm in Hamilton Breast Neoplasm in Kitchener Breast Neoplasm in London Breast Neoplasm in Halifax Breast Neoplasm in New York Breast Neoplasm in Los Angeles Breast Neoplasm in Chicago Breast Neoplasm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease